5-Amino-1MQ and fat loss: what the research actually shows

A recent TikTok video from shesfuntho highlights 5-amino-1MQ (often referred to as “5 amino”) as a peptide of interest for body composition. The creator claims that in clinical studies, this compound caused a reduction in white adipose tissue without reducing caloric intake, and that it works by improving NAD recycling rather than flooding the body with precursors. The video also mentions a favorable side-effect profile and affordability.

What the clip claims

The central claim is that 5-amino-1MQ can reduce fat mass independently of diet, by modulating NAD metabolism. The creator suggests it is distinct from other peptides because it enhances the body’s ability to recycle NAD, rather than simply supplying more precursors. The video also implies that clinical evidence supports these effects.

What the research neighborhood actually covers

5-amino-1MQ is a small molecule that has been studied in preclinical models, primarily in mice, for its effects on nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that consumes NAD+ and methyl groups. By inhibiting NNMT, 5-amino-1MQ is thought to increase NAD+ availability and promote a metabolic state that favors fat oxidation.

Published studies in rodent models have shown that NNMT inhibition can reduce white adipose tissue mass and improve glucose tolerance, even without changes in food intake. These findings are promising and have generated interest in the compound as a potential therapeutic for obesity and metabolic disorders.

However, it is critical to note that these are preclinical studies, not human clinical trials. As of now, there is no published peer-reviewed evidence from human trials demonstrating that 5-amino-1MQ reduces fat mass in people. The phrase “clinical studies” used in the video may be misleading, as the available data come from animal models.

Limits and research-use caveat

For research-use-only (RUO) products, the intended audience is scientists and researchers, not consumers. The safety, efficacy, and appropriate dosing of 5-amino-1MQ in humans have not been established. The “virtually no side effects” comment is based on limited animal data and does not guarantee safety in humans.

Furthermore, the claim that it works on the same system as NAD and MOTS-c is plausible, but the exact interplay is not fully understood. While 5-amino-1MQ may influence NAD recycling, the clinical relevance remains speculative.

In summary, the social media claim overstates the evidence by implying human clinical support. The research is intriguing but preliminary. For those considering RUO peptides, it is essential to adhere to laboratory protocols and consult primary literature.

Open the full video fact-check page (transcript, takeaways, embedded clip).